南通地区无偿献血者HPV B19、HAV和HEV感染状况研究  

HPV B19,HAV and HEV infection among voluntary blood donors in Nantong

作　　者：王克成 丁颍周 WANG Kecheng;DING Yingzhou(Nantong Blood Center,Nantong 226014,China)

机构地区：[1]南通市中心血站,江苏南通226014

出　　处：《中国输血杂志》2023年第5期444-447,共4页Chinese Journal of Blood Transfusion

摘　　要：目的评估献血者常规核酸筛查同时进行人细小病毒B19(HPV B19)、甲型肝炎病毒(HAV)和戊型肝炎病毒(HEV)核酸联合检测的可行性,分析南通地区无偿献血者HPV B19、HAV和HEV感染状况,为制定合理的献血者血液筛查方案提供数据。方法对2021年11月—2022年5月南通地区无偿献血者,采用核酸检测(NAT)方法检测其HPV B19 DNA、HAV RNA和HEV RNA,对核酸检测反应性标本进行血清学抗体检测。结果3440名无偿献血者中HPV B19 DNA检出3例,阳性率0.09%,其中2例HPV B19 DNA阳性献血者HPV B19-IgM为阴性,1例因标本量不足未能检测;3440例献血者中HAV RNA和HEV RNA未检出。HBV、HCV、HIV核酸筛查同步进行HPV B19、HAV和HEV核酸检测,较常规工作约延缓20 min发放检测报告。结论南通地区无偿献血者HPV B19,HAV和HEV核酸阳性率较低,但仍然存在输血传播感染风险,核酸检测可以降低其输血传播风险。Objective To evaluate the viability of nucleic acid test(NAT)of human parvovirus B19(HPV B19),hepatitis A virus(HAV)and hepatitis E virus(HEV)along with routine NAT for voluntary blood donors,and to analyze HPV B19,HAV and HEV prevalence in Nantong,so as to provide reference for rational blood screening programs.Methods HPV B19 DNA,HAV RNA and HEV RNA of blood donors in Nantong from November 2021 to May 2022 were detected using NAT,and serological antibody testing was performed on NAT reactive samples.Results Three HPV B19 DNA was yielded out of 3440 blood donors,with a positive rate of 0.09%,among which 2 were negative for HPV B19-IgM and 1 was undetermined due to insufficient sample size.HAV RNA and HEV RNA were not detected in 3440 blood donors.HPV B19,HAV,and HEV NAT were conducted simultaneously with routine HBV,HCV and HIV screening,prolonging the test reports by 20 minutes.Conclusion Although the HPV B19 DNA,HAV RNA and HEV RNA prevalence among voluntary blood donors in Nantong is low,the risk of transfusion transmitted infection still exsits and can be reduced by NAT.

关 键 词：人细小病毒B19 甲型肝炎病毒 戊型肝炎病毒 核酸检测 无偿献血者 

分 类 号：R457.1[医药卫生—治疗学] R373.2[医药卫生—临床医学]